Cipla Medpro South Africa Limited (CMSA) is a South African-based pharmaceutical company. CMSA with its subsidiaries is engages in the manufacture, marketing and supply of pharmaceutical products. CMSA operates mainly through two divisions, Cipla Medpro Manufacturing and Cipla Medpro, with Cipla Medpro Manufacturing producing mainly for the Company. It has two segments: single exit price (SEP), which includes Scheduled products for both private and tender business and over the counter (OTC), which includes non-scheduled products, as well as schedule 0, 1 and 2, which are available over the counter, both private and tender business. Its subsidiaries include Cipla Medpro Manufacturing (Pty) Limited, Galilee Marketing (Pty) Limited, Inyanga Trading 386 (Pty) Limited and Xeragen Laboratories (Pty) Limited. The Company acquired 100% of Cipla Medpro Botswana (Pty) Limited in June 2011. The Company acquired an additional 25% interest in Cipla Nutrition (Pty) Limited in December 2011.
